Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BOLD: BAF312 in Relapsing-Remitting Multiple Sclerosis
NCT00879658Phase 2Completed
- Sponsor
- Novartis
- Start
- Mar 2009
- Primary completion
- May 2011
- Modality
- Small Molecules
- Countries
- 12
01
Overview
A Phase 2 trial of siponimod in relapsing-remitting multiple sclerosis (RRMS), sponsored by Novartis. Started Mar 2009; status: completed.
02
Drugs
siponimod
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on NCT00879658.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00879658.